Stockscreener 앱 받기
1.12
1.82%
0.02
시간 외 거래:
1.13
0.010
+0.89%
전일 마감가:
$1.10
열려 있는:
$1.11
하루 거래량:
436.62K
Relative Volume:
1.01
시가총액:
$102.90M
수익:
-
순이익/손실:
$-30.15M
주가수익비율:
-1.2308
EPS:
-0.91
순현금흐름:
$-31.63M
1주 성능:
+4.67%
1개월 성능:
-2.61%
6개월 성능:
+94.04%
1년 성능:
-13.18%
1일 변동 폭
$1.065
$1.13
1주일 범위
$1.02
$1.16
52주 변동 폭
$0.49
$1.55
Context Therapeutics Inc Stock (CNTX) Company Profile
명칭
Context Therapeutics Inc
전화
267-225-7416
주소
2001 MARKET STREET, PHILADELPHIA
CNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.12 | 101.07M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | JMP Securities | Mkt Outperform |
| 2024-11-25 | 개시 | D. Boral Capital | Buy |
| 2024-05-16 | 개시 | Piper Sandler | Overweight |
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
SJVN Limited (533206) Stock Experiences Sudden DipMoving Average Strategies & Free Tremendous Portfolio Expansion - Bollywood Helpline
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Context Therapeutics (NASDAQ:CNTX) Shares Up 8.7% – What’s Next? - Defense World
Oncotelic Therapeutics Study Reveals Context-Dependent Biomarker Significance in Liver and Pancreatic Cancers - citybuzz
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer - The Manila Times
Oncotelic Therapeutics and Brush and Key Foundation - GlobeNewswire
Unpacking Q3 Earnings: CoStar (NASDAQ:CSGP) In The Context Of Other Data & Business Process Services Stocks - Yahoo Finance
Context Therapeutics Inc (CNTX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN
Is Context Therapeutics Inc. stock attractive for growth ETFs2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Unpacking Q3 Earnings: Axon (NASDAQ:AXON) In The Context Of Other Aerospace and Defense Stocks - Yahoo Finance
Why Context Therapeutics Inc. stock remains on buy listsMarket Growth Report & Momentum Based Trading Signals - BỘ NỘI VỤ
CT-202, a tumor-selective pH-dependent Nectin-4/CD3 TCE - BioWorld MedTech
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Average Target Price from Brokerages - Defense World
Ag Growth International (AGGZF) Projected to Post Quarterly Earnings on Friday - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Upgraded to “Sell” at Wall Street Zen - Defense World
Context Therapeutics (NASDAQ:CNTX) Upgraded to "Sell" at Wall Street Zen - MarketBeat
What drives Context Therapeutics Inc stock priceTrading Volume Trends & Affordable Growth Strategies - earlytimes.in
Jim Cramer Discusses Rockwell (ROK) Automation in the Context of Ongoing Industrial Revolution - Yahoo Finance
What technical charts say about Context Therapeutics Inc. stockWeekly Stock Analysis & Free Fast Gain Swing Trade Alerts - newser.com
Why analysts remain bullish on Context Therapeutics Inc. stockSwing Trade & Accurate Intraday Trading Signals - newser.com
Is Context Therapeutics Inc. stock a safe buy before earnings2025 Performance Recap & Technical Entry and Exit Alerts - newser.com
Is Context Therapeutics Inc. stock poised for growthJuly 2025 Decliners & Long-Term Growth Plans - newser.com
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks - Yahoo Finance
Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly - MyChesCo
Using portfolio simulators with Context Therapeutics Inc. includedMarket Growth Report & Long-Term Capital Growth Ideas - newser.com
Published on: 2025-11-16 17:23:15 - newser.com
Unpacking Q3 Earnings: Take-Two (NASDAQ:TTWO) In The Context Of Other Consumer Internet Stocks - Yahoo Finance
What’s the recovery path for long term holders of Context Therapeutics Inc.Market Risk Report & Daily Stock Momentum Reports - newser.com
Is Context Therapeutics Inc. stock resilient to inflationJuly 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
Published on: 2025-11-15 13:42:26 - newser.com
Exit strategy if you’re trapped in Context Therapeutics Inc.July 2025 WrapUp & AI Enhanced Trading Alerts - newser.com
Is Context Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Trade Ideas & Smart Money Movement Alerts - newser.com
Is Context Therapeutics Inc. stock positioned well for digital economyGlobal Markets & Risk Controlled Daily Plans - newser.com
How institutional buying supports Context Therapeutics Inc. stockAnalyst Downgrade & Stepwise Trade Signal Guides - Fundação Cultural do Pará
Does Context Therapeutics Inc. stock trade at a discount to peers2025 Dividend Review & Verified Entry Point Detection - newser.com
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
Context Therapeutics Inc (CNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.62%
자본화:
|
볼륨(24시간):